Net revenue rose 6.6% to €1.41 billion in H1 2026, driven by Rare Diseases growth and strong product performance. EBITDA margin improved to 38.3%, and adjusted net income increased 6.7%. Full-year guidance is confirmed, with continued investment in pipeline and strategic collaborations.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.